Cancer by Howard, David H. et al.
Comorbidities, Smoking Status, and Life Expectancy Among 
Individuals Eligible for Lung Cancer Screening
David H. Howard, PhD1, Thomas B. Richards, MD2, Peter B. Bach, MD3, Michelle C. Kegler, 
PhD4, and Carla J. Berg, PhD4
1Department of Health Policy and Management, Winship Cancer Institute, Emory University, 
Atlanta, Georgia
2Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and 
Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
3Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, 
New York
4Department of Behavior Science and Health Education, Emory University, Atlanta, Georgia
Abstract
BACKGROUND—Lung cancer screening recommendations are based on results from the 
National Lung Screening Trial (NLST). The authors determined how the screening-eligible US 
population differs from NLST participants in terms of characteristics that affect their ability to 
benefit from screening.
METHODS—The authors identified respondents to the 2012 Health and Retirement Study 
(HRS), a national survey of individuals aged ≥50 years who are eligible for screening based on US 
Preventive Services Task Force and Centers for Medicare and Medicaid Services criteria. 
Comorbidities, life expectancy, smoking history, and other characteristics were compared between 
the screening-eligible population and NLST participants.
RESULTS—The authors estimated that in 2013, 8.4 million individuals (95% confidence 
interval, 7.9–8.9 million individuals) would have met the eligibility criteria for lung cancer 
screening established by the US Preventive Services Task Force. Compared with NLST 
participants, HRS screening-eligible respondents were older, more likely to be current smokers, 
and more likely to have been diagnosed with comorbidities. The 5-year survival rate was 87% in 
the HRS screening-eligible individuals versus 93% in the NLST participants (P<.001, based on a 
2-sided test). Life expectancy was 18.7 years in the HRS screening-eligible individuals versus 
21.2 years in the NLST participants.
CONCLUSIONS—The US population eligible for lung cancer screening is probably less likely 
to benefit from early detection than NLST participants because they face a high risk of death from 
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competing causes. The results of the current study highlight the need for smoking cessation 
interventions targeting those patients eligible for screening and tools to help clinicians determine 
the potential benefits of screening in individual patients.
Keywords
comorbidity; early detection of cancer; life expectancy; lung neoplasms; population 
characteristics; smoking
INTRODUCTION
In 2013, the US Preventive Services Task Force (USPSTF), a US government advisory 
panel, recommended that adults aged 55 to 80 years who have a smoking history of 30 pack-
years and who currently smoke or have quit within the past 15 years undergo annual low-
dose computed tomography (LDCT) scans to screen for lung cancer.1 In 2015, the Centers 
for Medicare and Medicaid Services (CMS) announced that Medicare, the government 
insurance program for disabled and elderly individuals, will cover lung cancer screening for 
asymptomatic Medicare beneficiaries aged 55 to 77 years who meet the USPSTF criteria for 
smoking status and history.2 These decisions, like much of the recent literature regarding the 
benefits of screening, rely heavily on results from the National Lung Screening Trial 
(NLST).3–6 The NLST was a US-based trial that randomized 53,454 adults enrolled between 
August 2002 and April 2004 at 33 US medical centers to receive 3 annual LDCT screens or 
chest x-rays. The characteristics and outcomes of NLST participants have been well-
described in trial publications,3–6 but to the best of our knowledge little is known regarding 
the characteristics of individuals eligible for screening. In 2010, the NLST reported on the 
characteristics of NLST participants compared with those of respondents to the Tobacco Use 
Supplement of the 2002 to 2004 US Census Bureau Current Population Survey.4 They found 
that trial participants were similar to trial-eligible individuals in the general population based 
on sex and race/ethnicity, but more trial participants were aged <70 years, were former (vs 
current) smokers, and were college-educated.
The comparisons in the 2010 NLST report need to be updated because the characteristics of 
the US population aged ≥65 years have changed over the last decade. Although the 
percentage of adults aged ≥65 years who were current smokers remained approximately the 
same between 2005 and 2013, the size of the US population aged ≥65 years has increased by 
approximately 15% between 2000 and 2010.7,8 In addition, although several reports have 
estimated the US population meeting the NLST criteria, these reports were published before 
the release of the 2013 USPSTF or 2015 CMS eligibility criteria, and therefore do not 
specifically address those recommendations.9–11
The objective of the current study was to provide an update regarding how the 
characteristics of NLST participants compare with more recent information concerning the 
US screening-eligible population. The results will be useful for determining the 
generalizability of the NLST findings to community practice and assessing the need for 
smoking cessation interventions and decision aids to facilitate the translation of screening 
recommendations into practice. We applied the 2013 USPSTF and 2015 CMS eligibility 
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criteria to respondents to the Health and Retirement Study (HRS).12 The HRS is a nationally 
representative, National Institute on Aging-sponsored panel survey designed to collect 
information regarding the US population of adults aged ≥50 years currently in or nearing 
retirement. At the time of the current analysis, 2012 was the most recent available year. In 
the current study, we compared the characteristics of NLST participants with those of our 
HRS-estimated screening-eligible population, including demographics, socioeconomic 
status, comorbidities, survival rates, and life expectancy.
MATERIALS AND METHODS
Data Source
We assessed the characteristics of NLST participants using the NLST participant file.13 We 
assessed the characteristics of the screening-eligible population using the HRS.12 
Respondents are surveyed every 2 years in the HRS. The sample is replenished every 6 
years to account for attrition. Only noninstitutionalized adults are eligible for inclusion 
initially, but respondents who move into nursing homes remain in the HRS panel. Response 
rates, which vary across survey waves and components, are mostly between 80% and 90%. 
Information regarding deceased respondents is collected from proxy subjects.
We categorized respondents’ smoking history using questions that asked if they ever 
smoked, whether they currently smoke, the number of cigarettes they smoke currently, the 
number of cigarettes they smoked when they smoked the most, the age or year they started 
smoking, and the age or year they stopped smoking. Table 1 presents unweighted counts of 
the number of respondents categorized by current smoking status and smoking history.
Sample Selection
The main study sample included respondents who were in the 2012 HRS survey sample and 
alive at the beginning of 2012. In separate analyses, we focused on respondents to the 2000 
HRS (to determine how the number of screening-eligible individuals has changed over time) 
and the 2006 HRS (to determine 5-year survival rates).
We considered a respondent to be eligible for lung cancer screening based on the USPSTF 
lung cancer screening recommendation if they: 1) were aged 55 to 80 years; 2) had at least a 
30-pack-year smoking history (1 pack-year is equivalent to smoking 1 pack of cigarettes [20 
cigarettes] a day for 1 year); and 3) currently smoked or had quit within the past 15 years. 
We classified respondents as eligible for lung cancer screening under fee-for-service 
Medicare if they met the USPSTF criteria for smoking history as well as: 1) self-reported 
that they were enrolled in Medicare Part B (which covers outpatient care); 2) self-reported 
that they were not enrolled in a Medicare Advantage Plan; and 3) were aged 55 to 77 years. 
In addition, we reported selected results for respondents who met the criteria described 
above but were enrolled in a Medicare Advantage Plan. Medicare Advantage Plans are 
offered as an alternative to the government-run fee-for-service plan and offer equivalent 
benefit levels. Medicare enrollees can choose whether to enroll in a Medicare Advantage 
Plan or the government-run plan.
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We calculated the number of individuals in each eligibility category using the 2012 HRS 
sample weights and the “svy: total” command in Stata statistical software (version 11; 
StataCorp LP, College Station, Tex). We used the weighted percentage of screening-eligible 
respondents in the 2012 HRS who reported that they received a flu shot within the past year 
as an upper bound estimate of patients’ compliance with preventive services 
recommendations. All statistical tests were 2-sided with an α level of 5%.
We compared age group, sex, race, ethnicity, educational attainment, smoking status, and 
comorbidities that are common and reported in both the NLST and HRS data (diabetes, heart 
disease, and stroke) between subjects in the NLST (including subjects in both the LDCT arm 
and the chest x-ray arm)3,4 and HRS screening-eligible respondents. We tested the 
significance of differences in age group using weighted logistic regressions. We ran separate 
regressions for each characteristic.
We measured survival time among HRS screening-eligible respondents in 2006, which 
aligns with approximately the midpoint of the NLST, beginning from the date they 
responded to the survey. Records were right-censored at December 31, 2012. We reported 
Kaplan-Meier curves for screening-eligible and non-screening-eligible respondents. Stata’s 
command for creating Kaplan-Meier curves does not permit the use of sample weights. As 
an alternative, we divided the sample weights, Wi for respondent i, by 1000; rounded the 
weights to the nearest integer; and created Wi/1000 replicates of each observation. We 
computed Kaplan-Meier curves using this modified sample. We compared 5-year survival 
rates between screening-eligible respondents in the HRS and participants in the control arm 
of the NLST using a large-sample Z-test for proportions.
We projected life expectancy for screening-eligible HRS respondents and, separately, NLST 
participants by: 1) estimating Weibull survival models, adjusting for age and sex; 2) using 
the estimated parameters of the model to calculate monthly age-specific and sex-specific 
mortality rates; 3) estimating age-specific and sex-specific survival curves using the 
maximum of the projected mortality rates from the Weibull model and US life table 
values14; 4) calculating age-specific and sex-specific life expectancies by summing the area 
under the survival curves; and 5) calculating the average life expectancy in the sample using 
these values.15 In step 3, survival at time t + 1 equals survival at time t multiplied by 1 
minus the percentage of individuals dying, , in which  is 
the mortality rate estimated form the Weibull model and  is the age-specific and sex-
specific US life table value. By incorporating US life table values, we assume that no one 
survives past age 100 years and ensure that life expectancy estimates are not unreasonably 
large. We used the survival curves to calculate age-specific and sex-specific life expectancy 
and calculated life expectancy (step 5 above) among various groups of HRS respondents 
and, separately, NLST participants by averaging across individuals in each group.
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There were 1775 respondents to the 2012 HRS who would have met the 2013 USPSTF 
criteria for lung cancer screening and 770 who would have met the 2015 CMS criteria. The 
results presented below used sample weights to create nationally representative estimates.
Table 2 displays estimated counts and 95% confidence intervals (95% CIs) for the number 
of individuals in the United States based on the HRS data who met the criteria set forth for 
lung cancer screening in 2013 by the USPSTF and in 2015 by the CMS. We estimated that 
8.4 million individuals in 2012 would have met the 2013 USPSTF criteria, and 3.8 million 
were aged 65 to 80 years, including individuals who were not enrolled in Medicare. In 2000, 
only 2.9 million individuals (95% CI, 2.7–3.2 million individuals) were aged 55 to 64 years 
and would have met the 2013 USPSTF criteria, whereas 4.6 million were aged 55 to 64 
years in 2012. Overall for 2012, 58% of individuals had received a flu shot within the prior 
year.
For respondents enrolled in fee-for-service Medicare in 2012, there were 2.5 million 
individuals aged 55 to 77 years who would have met the 2015 CMS criteria for lung cancer 
screening. Of these, 2.0 million were aged 65 to 77 years. Overall for 2012, 70% of CMS 
screening-eligible beneficiaries (of all ages) received a flu shot.
We estimated that there were 1.1 million Medicare Advantage members in 2012 who were 
aged 55 to 77 years and would have met the 2015 CMS criteria for lung cancer screening 
(95% CI, 0.9–1.3 million individuals). There were 3.5 million individuals aged 65 to 77 
years, including individuals not enrolled in Medicare, who would have met the 2015 CMS 
criteria (95% CI, 3.2–3.8 million individuals).
Comparing the characteristics of NLST participants with those of 2012 HRS screening-
eligible respondents who would have met the 2013 USPSTF screening criteria, NLST 
participants were younger; more likely to have a college degree; less likely to be a current 
smoker; and less likely to have been diagnosed with diabetes, heart disease, or stroke (Table 
3). The results comparing characteristics of NLST participants with those of 2012 HRS 
screening-eligible respondents enrolled in fee-for-service Medicare and who would have 
met the 2015 CMS screening criteria were similar to those for the NLST participants versus 
the 2013 USPSTF criteria (Table 3).
Figure 1 displays Kaplan-Meier survival curves for NLST participants (the top curve) and 
the HRS respondents who would have met the 2013 USPSTF lung cancer screening criteria. 
Estimates for HRS respondents were adjusted for sampling weights, as described earlier, but 
we refer to survival among “respondents” for ease of explication. Each curve shows results 
for a different group of HRS screening-eligible respondents. The 5-year survival rates 
among HRS screening-eligible respondents in 2006 were significantly lower than the 95% 
survival rate observed among participants in the NLST (P<.001 in each case).
We estimated that life expectancy among NLST participants was 21.2 years. We estimated 
life expectancy among HRS screening-eligible respondents aged 55 to 74 to be 19.6 years. 
The difference reflects differences in the age and sex distribution between NLST 
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participants and the US population (as captured by the HRS sample weights) as well as 
differences in survival within age and sex groups. Life expectancy among HRS screening-
eligible respondents aged 55 to 80 years, the age range for which screening is recommended 
by the USPSTF, was 18.7 years. Life expectancy was found to be 14.0 years among HRS 
screening-eligible respondents enrolled in fee-for-service Medicare who were aged 55 to 77 
years. Figure 2 shows survival and life expectancy estimates among respondents aged ≥65 
years.
DISCUSSION
Most of what we know about the benefits and harms of screening for lung cancer with 
LDCT is based on data from the NLST.5,6,16,17 The benefits and harms of screening vary 
based on the risk of lung cancer and the risk of death from competing causes. Compared 
with the characteristics of NLST participants, the results of the current study demonstrated 
that the screening-eligible US population differed in several respects. Individuals eligible for 
screening in the general population included a higher percentage of current smokers; faced a 
higher risk of death from lung cancer; and, all else being equal, were substantially more 
likely to benefit from screening. However, individuals eligible for screening in the United 
States were also found to be older, more likely to have comorbidities, and to have higher 
mortality rates and shorter life expectancies.
Pinsky et al reported that, in the NLST, the false-positive rate was higher in Medicare-
eligible participants compared with those aged <65 years (27.7% vs 22.0%), invasive 
diagnostic procedures after false-positive screening results were more frequent in the older 
cohort compared with those aged <65 years (3.3% vs 2.7%), and complications from 
invasive procedures were in the range of 9% to 10% for both groups.6 Estimates of the 
overdiagnosis rate based on NLST data ranged from 9.9% to 18.5% of screen-detected 
cases.18,19 As lung cancer screening is implemented in the United States, surveillance will 
be needed to monitor whether community practice has higher false-positive results, 
overdiagnosis, or major complications from invasive procedures than observed in the NLST.
The findings of the current study are relevant for efforts to increase the capacity of the 
health system to deliver lung cancer screening in community practice. We found that 8.4 
million individuals would have met the USPSTF criteria for lung cancer screening in 2012. 
Our estimate is close to estimates of the screening-eligible population aged 55 to 74 years 
based on NLST criteria and the 2010 National Health Interview Survey (approximately 8.7 
million).10,11 Although the national landscape is likely to change the 2015 CMS coverage 
decision, studies conducted before 2015 have suggested additional lung cancer screening 
programs and radiologists would be needed to provide screening services to all the 
individuals who meet the USPSTF screening criteria.20,21 An additional resource-related 
question is whether adherence to annual lung cancer screening in community practice will 
be similar to the NLST. Adherence to lung cancer screening was >90% in the NLST, but 
this occurred within the context of a randomized trial.3 NLST participants volunteered for 
the trial and would not necessarily have the same characteristics or motivations as a random 
sample of all eligible patients in a community. We found that only 58% of the lung cancer 
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screening-eligible population received a flu shot; thus, compliance with lung cancer 
screening in community practice might not be as high as observed in the NLST.
The projected benefits of lung cancer screening are highly dependent on how screening 
affects smoking rates.22 The Agency for Healthcare Research and Quality’s Treating 
Tobacco Use and Dependence clinical guidelines23 indicate that: 1) pharmacotherapy is 
effective in the treatment of nicotine dependence; 2) behavioral counseling is effective in the 
treatment of nicotine dependence; and 3) the combination of both is more effective than 
either alone. The CMS decision regarding final coverage requires that screening-eligible 
beneficiaries who are current smokers receive smoking cessation counseling and 
information regarding tobacco cessation interventions.2 The results of the current study 
indicate that the screening-eligible population will have higher smoking rates than those 
noted among NLST participants, thus creating a substantial demand for cessation services. 
The mandate to integrate smoking cessation into screening services capitalizes on a 
“teachable moment” that may coincide with an individual undergoing lung cancer 
screening.24 Full implementation of effective smoking cessation services will be an 
important addition to community practice; in 2010, < 50% of smokers in the United States 
had been advised by a physician to quit.25 A recent examination of smoking cessation 
among current smokers in the NLST demonstrated higher quit rates among those who 
reported their primary care providers had completed the more intensive components of the 
5As (ask, advise, assess, assist [talk about quitting or recommend stop-smoking medications 
or counseling], and arrange follow-up): assist and arrange.26 Thus, greater efforts are needed 
to integrate cessation services into clinical practice, particularly given that physician 
involvement can play a critical role in smoking cessation.23
The current study is based on the HRS survey, which relies on respondent self-report for 
collecting data regarding smoking and health conditions. Health conditions among NLST 
participants also were assessed via self-report.2 Our estimates may be biased by systematic 
differences between survey respondents and nonrespondents and by misreporting by 
respondents. The estimates in the current study are based on 2012 HRS data, which were 
published before the 2013 USPSTF and 2015 CMS recommendations were released. These 
estimates do not reflect any changes in the size or composition of the screening-eligible 
population after 2012.
The results of the current study demonstrate that the screening-eligible US population differs 
from NLST participants in important respects that influence the potential benefits of 
screening vary so widely within the screening-eligible population, it is important for 
physicians to tailor screening recommendations to individual patients.17 CMS requires as a 
condition of coverage that clinicians engage in shared decision-making with beneficiaries 
before lung cancer screening. We found that < 12% of eligible patients have a college 
degree, suggesting that clinicians may find it challenging to communicate concepts such as 
“competing risks” and “false-positives” with screening-eligible patients. Patient decision 
support tools can help to bridge the communication gap,27–29 but they should incorporate 
information regarding the risks associated with invasive procedures and how the benefits of 
early detection are related to the risk of death from competing causes.
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Survival among screening-eligible individuals and National Lung Screening Trial (NLST) 
participants. HRS indicates Health and Retirement Study; LE, life expectancy; USPSTF, US 
Preventive Services Task Force.
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Survival among screening-eligible individuals and National Lung Screening Trial (NLST) 
participants aged ≥ 65 years. HRS indicates Health and Retirement Study; LE, life 
expectancy.
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TABLE 1
Unweighted Counts of Respondents to the 2012 HRS Survey
Category
All Ages Aged 55 to 80 Years
No. % No. %
Meets USPSTF criteria for lung cancer screening 2223 9.4 1775 10.5
Current smoker, ≥ 30 pack-y 1332 5.6 1066 6.3
Former smoker, ≥ 30 pack-y, quit within past 15 y 891 3.8 709 4.2
Other former or current smokers 10,673 45.0 7654 45.3
Current smoker, < 30 pack-y 1828 7.7 1250 7.4
Current smoker, missing pack-y 153 0.6 113 0.7
Former smoker, < 30 pack-y, quit within past 15 y 1235 5.2 872 5.2
Former smoker, missing pack-y, quit within past 15 y 9 0.0 9 0.1
Former smoker, quit > 15 y ago 7043 29.7 5107 30.2
Smoker, missing pack-y and current smoking status 405 1.7 303 1.8
Never smoked 10,357 43.6 7190 42.5
Smoking status missing 477 2.0 282 1.7
Total 23,730 100.0 16,901 100.0
Abbreviations: HRS, Health and Retirement Study; USPSTF, United States Preventive Services Task Force.
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TABLE 2
Estimates of the Number of Smokers (in Millions) in the 2012 HRS Survey Who Met the 2013 USPSTF and 
2015 Medicare Lung Cancer Screening Criteriaa
Age Group
USPSTFb Medicare FFSc
No. 95% CI No. 95% CI
55–64 4.6 4.2–5.0 0.6 0.42–0.69
65–74 3.1 2.8–3.4 1.7 1.49–1.91
75–77 0.3 0.22–0.35
75–80 0.7 0.6–0.8
Total 8.4 7.9–8.9 2.5 2.28–2.79
Abbreviations: 95% CI, 95% confidence interval; FFS, fee-for-service; HRS, Health and Retirement Study; LE, life expectancy; USPSTF, US 
Preventive Services Task Force.
a
Estimates were weighted to produce nationally representative results.
b
In 2013, the USPSTF recommended lung cancer screening with low-dose computed tomography in adults aged 55 to 80 years who have a 30 
pack-year smoking history and currently smoke or have quit within the past 15 years.
c
Medicare covers screening for beneficiaries aged 55 to 77 years who have a 30 pack-year smoking history and currently smoke or have quit within 
the past 15 years.
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